Seonix Bio is proud to announce that it has received accreditation to ISO 15189 by the National Association of Testing Authorities, Australia (NATA), for its age-related macular degeneration (AMD) polygenic risk score. This accreditation recognises the quality, accuracy, and reliability of Seonix Bio’s laboratory processes supporting the delivery of advanced genomic risk assessment for AMD.

“Our newly accredited AMD polygenic risk score reflects Seonix Bio’s commitment to empowering clinicians and patients with robust, clinically meaningful genetic insights,” said Nick Haan, CEO at Seonix Bio. “We are dedicated to advancing precision eye health through scientifically validated, high-quality testing.”

NATA accreditation underscores Seonix Bio’s ongoing focus on operational excellence, ensuring its services continue to meet rigorous national and international standards while supporting improved outcomes in eye health.

Seonix Bio is proud to announce that it has received accreditation to ISO 15189 by the National Association of Testing Authorities, Australia (NATA), for its age-related macular degeneration (AMD) polygenic risk score. This accreditation recognises the quality, accuracy, and reliability of Seonix Bio’s laboratory processes supporting the delivery of advanced genomic risk assessment for AMD.

“Our newly accredited AMD polygenic risk score reflects Seonix Bio’s commitment to empowering clinicians and patients with robust, clinically meaningful genetic insights,” said Nick Haan, CEO at Seonix Bio. “We are dedicated to advancing precision eye health through scientifically validated, high-quality testing.”

NATA accreditation underscores Seonix Bio’s ongoing focus on operational excellence, ensuring its services continue to meet rigorous national and international standards while supporting improved outcomes in eye health.